Smart Inhalers Market Introduction and Overview
According to SPER Market Research, the Global Smart Inhalers Market is estimated to reach USD 110.83 billion by 2034 with a CAGR of 19.65%.
The report includes an in-depth analysis of the Global Smart Inhalers Market, including market size and trends, product mix, Applications, and supplier analysis.
The market for smart inhalers was valued at USD 18.43 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 19.65% between 2024 and 2030. The market is anticipated to rise as a result of the increasing incidence of chronic respiratory diseases (CRDs) worldwide, the creation of goods with cutting-edge technology, and the expanding use of digital solutions in the healthcare industry. Furthermore, according to WHO predictions, by 2030, almost one in five fatalities globally would be attributable to potentially lethal respiratory diseases, such as tuberculosis, lung cancer, and COPD.
Our in-depth analysis of the Global Smart Inhalers Market includes the following segments:
By Type Insights
The market is divided into dry powdered inhalers (DPIs) and metered dose inhalers (MDIs). In 2023, MDIs held the largest revenue share due to their ease of use and efficiency in delivering fixed doses through inhalation. In September 2022, OzUK Limited partnered with H&T Presspart to provide generic MDIs for COPD/Asthma applications.
By Indication Insights
The market is divided into COPD, asthma, and others. COPD had the largest revenue share in 2023 due to its global prevalence. The asthma segment is expected to grow significantly over the forecast period, driven by rising cases and increased demand for smart inhalers and innovative solutions.
By Distribution Channel Insights
The hospital pharmacies segment had the largest revenue share in 2023. They provide more flexibility, comfort, and convenience for buying smart inhalers for hospitalized patients. Rising cases of chronic respiratory illnesses have led to more patients in hospitals, making it easier for them to purchase smart inhalers nearby, boosting segment growth.
By End Use Insights
Hospitals had the biggest revenue share in 2023. Quick improvements in healthcare infrastructure, growing public-private partnerships, and better access to services are expected to greatly affect hospitals. They also quickly use smart inhaler technology for patients with respiratory diseases. The rising number of patients pushes hospitals to keep a large stock of various smart inhalers.
By Regional Insights
North America dominated the global smart inhalers market in 2023. Key factors for this growth include the region's strong healthcare infrastructure, rising cases of COPD and asthma, and the use of advanced medical devices. Regulatory bodies also support solutions for respiratory diseases.
Market Competitive Landscape
Key competitors in the respiratory industry are using collaborations, mergers and acquisitions, and new product development to grow their market share. Notable firms include Teva Pharmaceuticals, 3M, Novartis, Adherium, Propeller Health, and COHERO Health. These companies are using various strategies to gain an edge over rivals.
Adherium Limited partnered with Trudell Medical in August 2022, combining Adherium's Hailie sensors with Trudell's U. S. operations and Aetonix's aTouchAway platform to assist COPD patients, aiming to improve patient outcomes and reduce readmissions.
Recent Developments:
- In April 2024, Adherium announced it received FDA clearance for its Hailie Smartinhaler with AstraZeneca’s Breztri and Airsupra inhalation devices. This clearance provides real-time insights through data collection into inhaler technique and medication usage.
- AstraZeneca and Honeywell formed a partnership in February 2022 to create new respiratory inhalers with propellant HFO-1234ze. This propellant has a Global Warming Potential (GWP) about 99.9% lower than current options, enhancing the company's market offerings.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Type, By Indication, By Distribution Channel, By End Use |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Presspart Verwaltungs GmbH, Personal Air Quality Systems Pvt Ltd, AptarGroup, Inc, Cognita Labs, Adherium, Amiko Digital Health Limited, Teva Pharmaceuticals Industries Ltd, ResMed, Novartis AG, Pneuma Respiratory Inc, 3M. |
Key Topics Covered in the Report:
- Global Smart Inhalers Market Size (FY’2025-FY’2034)
- Overview of Global Smart Inhalers Market
- Segmentation of Global Smart Inhalers Market By Type (Dry Powdered Inhalers, Metered Dose Inhalers)
- Segmentation of Global Smart Inhalers Market By Indication (Asthma, COPD, Others)
- Segmentation of Global Smart Inhalers Market By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- Segmentation of Global Smart Inhalers Market By End Use (Hospitals, Homecare Settings, Others)
- Statistical Snap of Global Smart Inhalers Market
- Expansion Analysis of Global Smart Inhalers Market
- Problems and Obstacles in Global Smart Inhalers Market
- Competitive Landscape in the Global Smart Inhalers Market
- Details on Current Investment in Global Smart Inhalers Market
- Competitive Analysis of Global Smart Inhalers Market
- Prominent Players in the Global Smart Inhalers Market
- SWOT Analysis of Global Smart Inhalers Market
- Global Smart Inhalers Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst